Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Thiolutin** is a dithiolopyrrolone and sulfur-containing antibiotic synthesized by various *Streptomyces* species, notably *Streptomyces luteosporeus*[1][10]. It displays broad-spectrum antibacterial and some antifungal activity, along with notable anti-angiogenic effects[1][3][10]. Thiolutin acts as a potent, reversible inhibitor of bacterial and yeast DNA-dependent RNA polymerases (types I, II, and III), thereby blocking RNA synthesis (transcription)[1][3][5][9][10]. It is also reported to inhibit certain JAMM domain zinc metalloproteases (e.g., Rpn11, Csn5, AMSH, Brcc36)[2][7], act as a zinc chelator, and disrupt cellular processes like mRNA degradation and cytoskeletal organization (via Hsp27 perturbation), which leads to the inhibition of endothelial cell adhesion and angiogenesis[1][2][3][6][7]. Thiolutin is primarily used as a research tool, including in the study of mRNA synthesis and stability, not as a human therapeutic agent[4][6][9]. Its effects are reversible, making it valued in experimental modulation of transcription[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on thiolutin.